Your AI-Trained Oncology Knowledge Connection!
Though these collective findings demonstrate that genetic predisposition to increased weight is protective against breast and prostate cancer, further research is still necessary to work out exactly how this protection is provided, especially in breast cancer.
Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.
Digital breast tomosynthesis plus synthetic mammography depicted more cancers and found a lower number of stage II cancers at repeat screening compared with FFDM.
Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.
The FDA issued an emergency use authorization for the second coronavirus 2019 disease vaccine, Moderna COVID-19 Vaccine, to be distributed in the U.S. for use in individuals 18 years of age and older.
The FDA approved the supplemental new drug application for ponatinib (Iclusig) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.
Full approval has been granted by the FDA to osimertinib (Tagrisso) for use as adjuvant therapy following tumor resection among patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
The expert in urologic oncology spoke about the advancements made in 2020, as well as areas of prostate cancer care which he believes remain to be improved.
Plinabulin in combination with pegfilgrastim reduced the incidence of chemotherapy-induced neutropenia, compared with pegfilgrastim alone, in patients with breast cancer undergoing chemotherapy with docetaxel, doxorubicin, and cyclophosphamide.
Relugolix (Orgovyx) is the first oral drug in its class to receive FDA approval for the treatment of adults with advanced prostate cancer.
Selinexor (Xpovio) earned full FDA approval in combination with bortezomib (Velcade) and dexamethasone for the treatment of multiple myeloma after 1 or more prior therapies based on the phase 3 BOSTON trial.
Clinical researcher Lisa La discussed advancements in multiple myeloma research and where she hopes the field continues to expand.
The breast medical oncologist and researcher discussed how the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal, lymph node-positive, HR-positive, HER2-negative breast cancer.
A new rituximab biosimilar from Amgen is now FDA approved, providing more treatment options to patients with certain hematologic cancers.
The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed which patient groups he believes require more attention.
Investigators suggested that these study results reveal a need to protect and monitor patients with cancer as part of the strategy to control the COVID-19 pandemic.
The FDA granted priority review to a new supplemental biologics license application for pembrolizumab (Keytruda) in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.
Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations
The FDA approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least 1 of which was for metastatic disease.
The ongoing GO29365 study of combination regimens containing polatuzumab vedotin (Polivy) for patients with relapsed or refractory diffuse large B-cell lymphoma added an additional 106 patients to confirm preliminary findings of safety and efficacy.
At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.
This study demonstrated that the concurrent use of this new artificial intelligence tool alongside mammography improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.
The clinical researcher discussed areas of multiple myeloma which she believes deserve further assessment.
The pivotal phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) met its dual primary end points of overall and progression-free survival in patients with advanced endometrial cancer.
Research presented at the 2020 SABCS found providers planned to use neoadjuvant endocrine therapy for as little as possible until surgery was available for patients with estrogen receptor positive breast cancer.
This study revealed that reliability, or patient interpretation of telemedicine as a substitute for in-person visits, of the platform was of the greatest concern to all patients.
The agent was designed as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, peripheral T-cell lymphoma, Burkitt’s lymphoma, and soft tissue sarcoma.
Payne and colleagues indicated that a significant number of adolescent and young adult women are still not being given the information they desire regarding fertility preservation and therefore are not making fully informed treatment decisions.
Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.
Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.
